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Samia Afzal, Muhammad Idrees* and Mazhar HussainAbstract
Hepatitis C virus (HCV) is a universal health issue and a significant risk factor leading to hepatocellular carcinoma.
HCV has infected approximately 170 million individuals worldwide. It is a member of Flaviviridae with positive sense
RNA genome. In the absence of any effective vaccine against HCV, pegylated interferon with ribavirin is the
standard of treatment against HCV infection. In this study, sequence and structural analysis of envelope 2 (E2)
protein was performed which was isolated from patients of HCV genotype 3a in Pakistan. Then, epitopes were
predicted which were specific for both B-cells and T-cells. Later, conservancy of epitopes was checked with the HCV
3a and 1a sequences from different countries. A total of 6 conserved epitopes were found from extra-membranous
regions of E2 protein. Presence of conserved epitopes in E2 protein generates the possibility that these epitopes
can be used to elicit the immune response against HCV.
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Hepatitis C virus (HCV) is a universal health issue and a
significant risk factor developing hepatocellular carcin-
oma (HCC). World Health Organization reported that
hepatic cancer caused by HCV scored about 300,000
deaths in 2004 only [1]. It has affected approximately
170 million individuals worldwide [2]. In United States,
HCV is most common blood-borne infection with over
4 million individuals infected [3]. According to a recent
study, an alarming 17 million people in Pakistan are in-
fected with HCV and about 8-10% of individuals are
carriers of HCV pathogen [4]. Prevalence analysis of
Pakistani population shows that HCV genotype 3a is the
most common genotype in all provinces except in
Balochistan where HCV genotype 1a is most prevalent [5].
HCV is a member of Flaviviridae and closely related to
Dengue, West Nile and Yellow Fever virus. It has a posi-
tive sense single stranded RNA genome of about 9.6 kb
size [6]. HCV genome encodes a large polyprotein of
3010 to 3033 amino acid residues [7,8]. This polyprotein* Correspondence: idreeskhan@cemb.edu.pk
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unless otherwise stated.is subsequently cleaved into four structural (Core, E1, E2
and P7) and 6 non structural proteins (NS2, NS3, NS4A,
NS4B, NS5A and NS5B) [9].
However, the structural details of the HCV virus are
still elusive [10], but it is known that infectious viral par-
ticles contains lipid envelope and glycoproteins E1 and
E2, close to the surface [11]. E2 is highly glycosylated
with most of the glycosylation sites well conserved [12].
In addition to these conserved residues, E2 has hyper-
variable regions which vary up to 80% among HCV of
different genotypes and even between the subtypes of
same genotype [13]. However, E2 protein interacts with
DC-SIGN and L-SIGN (mannose binding proteins) but
detailed mechanism of viral entry is unclear. It is sug-
gested that glycosylated motifs of E2 protein interacts
with surface receptor enabling the viral entry into the
cell [14]. Hence, E2 protein is a potent target to stop
viral entry into healthy cells [15].
Currently, the pegylated interferon (IFN) alpha, separ-
ately or in combination with ribavirin, is standard HCV
treatment [16-18]. The efficacy of IFN treatment de-
pends on many factors related to viral genotype and pa-
tient’s health status. Clinical studies show that in 30-50%
of cases HCV remain non-responsive to IFN treatmentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 PCR amplification of HCV E2 protein from HCV
patients. The gel shows 1056 bp (1 – 4) gene products and their
molecular weight is compared to 1 kb ladder (M).
Figure 2 EcoR1 digestion of E2 carrying pCR2.1 vectors. For the
comparison of DNA sizes, 1 kb ladder (M) is used. The restriction
digestion reactions (1 – 4) shows 1056 bp band of E2 gene and
3900 bp band of linearized pCR2.1 (TA) vector.
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associated with treatment [9]. In spite of advancements
in drug designing technologies, there is still no vaccine
against HCV. Variability across the HCV genotypes is
also a significant hindrance in vaccine development.
For the development of potential inhibitors against en-
velope proteins, it is required to have knowledge of se-
quence and structure of protein. With the development
of computational biology, novel approaches have been
developed to get insights from biological data. This
study was designed to isolate E2 glycoprotein sequence
from HCV genotype 3a infected patient; and to predict
and to analyze the epitopes related to B-cells and T-
cells. The conservation and variability analysis was in-
cluded to find spectrum of activity of epitopes in HCV
genotype 3a and 1a.
Methodology
Source of serum samples
HCV genotype 3a samples were collected from patients
diagnosed with HCV at Molecular Diagnostics Lab.
CEMB, Lahore. The informed consent was taken from
the patients and blood sample was taken according to
provision of Ethical Committee, Molecular Virology
Division, National Centre of Excellence in Molecular
Biology, Lahore. The patients were selected on the basis
of elevated serum ALT and AST levels at least for six
months, histological examination, and detection of
serum HCV RNA anti-HCV antibodies (3rd generation
ELISA).
RNA isolation from serum, cDNA synthesis and
sequencing of HCV E2 gene
Total RNA was isolated from patients’ serum samples
using Gentra RNA isolation kit (Puregene, Minneapolis,
MN55441 USA) according to the kit protocol. Then, ex-
tracted RNA was reverse transcribed to cDNA using
MMLV-RTase (Moloney murine leukemia virus reverse
transcriptase). By using the E2 specific primers, E2 gene
was amplified using cDNA of HCV genotype 3a. For
this, PCR protocol involved 35 cycling steps at annealing
temperature 54°C. The amplified PCR product was re-
solved using 1.2% TAE agarose gel and molecular weight
was compared with 1 kb DNA ladder. Then, DNA was
purified from gel using QIA quick gel extraction kit
(Qiagen, USA) using the kit protocol. Purified PCR
product was cloned in pCR2.1-TOPO (TA vectors) ob-
tained from Invitrogen, USA. Successful cloning was
confirmed by PCR using E2 specific primers and by di-
gestion of construct using EcoR1 at 37°C for 1 hr. Later,
a sequencing reaction was performed using BigDye™
Terminator v3.0 sequencing kit (Applied Biosystems,
Germany). Both positive and negative strands were se-
quenced at automated sequencer (Applied Biosystems3700 DNA Analyzer, Germany). Then, the gene se-
quence was submitted at NCBI GenBank, having acces-
sion no. ADP55199.Sequence analysis of E2 protein
HCV 3a E2 gene sequence ADP55199 was used for pri-
mary structure analysis and for the prediction of second-
ary as well as three-dimensional structure. The E2 gene
sequence was in-silico translated to obtain primary
structure (amino acid sequence) of protein. Primary
structure parameters of E2 protein which include mo-
lecular weight, theoretical pI, atomic composition, ex-
tinction coefficient, estimated half-life, aliphatic index
Figure 3 The glycosylation sites prediction and conservancy in these sites in E2 proteins from different regions of world.
Table 1 Predicted disulfide bonds
Predicted bonds
46 – 267 RTALNCNDSIN – RLSAACNWTRG
69 – 104 FNSTGCPSMLS – DDKPYCWHYAP
76 – 187 SMLSSCKPITF – CGAPSCDIYGG
112 – 275 YAPRSCSTVPA – TRGERCDIEDR
121 – 170 PASSVCGPVYC – GRWFGCVWMNS
126 – 208 CGPVYCFTPSP – FCPTDCFRKHP
160 – 204 FLLESCGPPSG – DTDLFCPTDCF
220 – 300 ATYSRCGAGPW – LAILPCSFTPM
230 – 243 WLTPRCMVDYP – LWHYPCTVNFT
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computed using ProtParam online tool [19]. Secondary
structure of the protein was analyzed using Jpred,
Psipred and “Sequence Annotated by Structure” (SAS)
tool [20-22]. Disulfide connectivity of the protein was
checked using DiANNA tool which is a neural network
application and predicts cysteine states of a protein [23].
The knowledge of cys-cys linkages is important in un-
derstanding the secondary and tertiary structure of pro-
tein because it plays significant role in fold stabilization.
Glycosylation sites were predicted using NetNGlyc 1.0
server and their conservancy was checked using multiple
sequence alignment by MEGA5.0 [24].
De novo protein modeling and quality assessment
For the prediction of three dimensional structure of E2
protein both homology modeling and de novo modeling
approaches were used. For the homology modeling,
BlastP was used for searching suitable template in Pro-
tein Data Bank (http://www.rcsb.org/pdb/home/home.
do). In our search, the appropriate template was not
found, so we used iTASSER server for de novo modeling
of E2 protein [25]. Using iTASSER, five models were
predicted and one best model was chosen for further
structural analysis. The selection of model was done
using three criteria: C-score, DFIRE2 energy profile [26]
and stereochemical properties using PROCHECK tool
[27]. The visual analysis of structure was done on Swiss-
PDB-viewer [28] and Visual Molecular Dynamics (VMD)
program [29].
Epitopes prediction from E2 protein
A systematic approach was employed for the prediction
of potential epitopes in E2 protein. Vexijen 1.0 was used
to determine overall antigenicity of E2 protein using cut-off value of 0.4 [30]. Then, topology of E2 protein was
determined using TMHMM Server v 2.0 [31]. With the
help of membrane topology data, E2 protein regions in-
side the membrane and transmembrane were eradicated
from epitopes prediction. BCPRED server was used for
the prediction of B-cell epitopes of the length of 12
amino acids [32]. For the prediction of T-cell epitopes
ProPred was used with proteasome cleavage site filter of
5% threshold. In this analysis, 47 alleles of MHC-class I
and 54 alleles of MHC-class II were included [33]. Once
the B-cells and T-cells (MHC-class I and MHC-class II)
epitopes were predicted, their antigenicity was checked
using Vexijen. The antigenicity score of the predicted epi-
topes was checked using Vexijen v 1.0 server. Later, only
antigenic epitopes were included in conservancy analysis.
The conservancy of epitopes
The E2 protein sequences of HCV genotype 3a and 1a were
retrieved from NCBI sequence database. The HCV 3a
sequences were from India (AGQ17416), Japan (BAN67274),
Figure 4 Sequence and structural analysis of E2 protein. (A) Secondary structure of the protein with respect to protein sequence and
(B) Ribbon representation of 3D structure of E2 protein selected model. Ramachandran plot (C) is showing the phi and psi angles distribution in
the protein while z-score (D) is representing the overall quality of model with respect to high resolution models.
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and HCV 1a sequences were from Pakistan (GU736411),
USA (EU482831), United Kingdom (AY958057), France
(AF529293) and Japan (AB520610). The conservancy and
variability of the predicted antigenic epitopes was deter-
mined by “IEDB conservancy analysis tool” [34] in E2 pro-
tein sequences retrieved from different regions of world.Then, all highly conserved epitopes were checked for their
localization in predicted protein structure.
Results and discussion
cDNA synthesis and cloning of E2 protein
Serum samples collected from HCV genotype 3a positive
individuals were processed for total RNA extraction.







160 CGPPSGRWFGCV 0.998 −0.7569
82 FNQGWGPLTDGN 0.969 0.9925
188 DIYGGNGRRGND 0.965 1.4612
136 TTDAKGVPTYNW 0.93 0.4148
29 QLINTNGSWHIN 0.916 0.7087
278 EDRDRSEQHPLL 0.892 0.5071
108 APRSCSTVPASS 0.849 -0.0164
221 GAGPWLTPRCMV 0.827 0.4537
203 FCPTDCFRKHPE 0.819 −0.1963
123 PVYCFTPSPVVV 0.812 0.9481
60 YRYRFNSTGCPS 0.806 0.9192
43 ALNCNDSINTGF 0.679 0.8184
95 SGPSDDKPYCWH 0.645 1.2504
174 NSTGFLKTCGAP 0.587 −0.3698
301 SFTPMPALSTGL 0.56 0.6394
234 YPYRLWHYPCTV 0.383 0.4361
265 AACNWTRGERCD 0.311 0.4919
252 VRMFVGGFEHRL 0.291 0.1934
Non-Antigens are shown in bold face.
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E2 gene was amplified using gene specific primers. The
PCR product was checked on the gel and bands were
observed at 1056 bp position with reference to 1 kb
DNA marker (Figure 1). DNA in the gel was used for
ligation in pCR2.1 for TA cloning. TA cloning was veri-
fied by PCR using E2 gene specific primers and EcoR1
digestion. The restriction digestion with EcoR1 produced
2 bands for each sample (Figure 2). A band with 3.9 kb
molecular weight indicates the linearized pCR2.1 and
the other with ~1.05 kb indicates the size of E2 gene.
One sample was further processed for sequencing, struc-
tural and epitope prediction.
Sequence analysis of E2 protein
In this study, we have employed sequence analysis, de
novo modeling and epitopes prediction from E2 protein
isolated from Pakistani patient. Its estimated molecular
weight is 38703.8 daltons and comprised of 352 amino
acids. The pI and extinction coefficient of the protein were
6.86 and 80995 M−1 cm−1, respectively. The protein has
GRAVY score of −0.122 which indicates that protein is
hydrophilic in nature. Glycosylation sites analysis revealed
the presence of eight potential glycosylation sites in the
protein (Figure 3). Among all, six sites at positions 34, 65,
93, 150, 174 and 246 were conserved in the sequences
retrieved from various regions of the world. The protein
also contains 9 disulfide bridges (Table 1) which renders
extracellular stability in proteins [35,36].
De novo models and quality assessment
Secondary structure of the protein shows that loops
make the 78% of the protein while sheets and helices
contribute 14% and 8% of the structure, respectively
(Figure 4A). Using iTASSER server, five protein models
were developed. The best model was selected by com-
bined evaluation based on C-score (confidence score
from iTASSER server), DFIRE2 energy profile and
stereochemical properties using Ramachandran plot. It
is very evident from Table 2 that Model1 is bestTable 2 Assessment of iTASSER predicted E2 protein models
Model 1 Model 2 Model 3 Model 4 Model 5
I-TASSER (C-score) −1.17 −3.11 −3.12 −3.17 −3.35
DFIRE2 −420.54 −586.18 −573.31 −579.41 −599.08
PROCHECK
Allowed 82.1% 69.4% 72.9% 69.8% 70.4%
Additionally
allowed
13.7% 19.6% 17.9% 19.6% 20.3%
Generously
allowed
2.7% 4.1% 5.2% 5.5% 3.8%
Disallowed 1.4% 6.9% 4.1% 5.2% 5.5%among all others based on C-score and Ramachandran
plot. In addition to this, secondary structures in three-
dimensional structure of Model1 have stronger correlation
with predicted secondary structures with other methods
(Figure 4B). As far as, Model1 stereochemical quality is
concerned, it showed 82.1% amino acid residues in
allowed and only 1.4% residues in disallowed region of
Ramachandran plot (Figure 4C). However, its DFIRE2
score was not better than other 4 models but its z-score
(−0.85) based on its overall energy was comparable with










128 TPSPVVVGT HLA-B_3501, HLA-B_5101, HLA-
B_5102, HLA-B_5103, MHC-Ld
1.5496




1 VTHTVGGSV HLA-B_5103, HLA-B_5301, HLA-
B_51, HLA-B_5801, HLA-B61
0.2406
Non-Antigens are shown in bold face.





28 LQLINTNGS DRB1_0101, DRB1_0102, DRB1_0301, DRB1_0305, DRB1_0306, DRB1_0307, DRB1_0308,
DRB1_0309, DRB1_0311, DRB1_0401, DRB1_0402, DRB1_0404, DRB1_0405, DRB1_0408,
DRB1_0410, DRB1_0421, DRB1_0423, DRB1_0426, DRB1_0802, DRB1_0804, DRB1_0806,
DRB1_0813, DRB1_1101, DRB1_1102, DRB1_1104, DRB1_1106, DRB1_1107, DRB1_1114,
DRB1_1120, DRB1_1121, DRB1_1128, DRB1_1301, DRB1_1302, DRB1_1304, DRB1_1305,
DRB1_1307, DRB1_1311, DRB1_1321, DRB1_1322, DRB1_1323, DRB1_1327, DRB1_1328,
DRB1_1506, DRB5_0101, DRB5_0105
−0.2636
64 FNSTGCPSM DRB1_0101, DRB1_0701, DRB1_0703, 0.6645
179 LKTCGAPSC DRB1_0101, DRB1_0102, -0.2346
31 INTNGSWHI DRB1_0102, DRB1_0402, DRB1_0701, DRB1_0703, 1.0793
124 VYCFTPSPV DRB1_0102, DRB1_0423, DRB1_1501, DRB1_1506 1.4124
154 VFLLESCGP DRB1_0102, DRB1_0404, DRB1_0408, DRB1_0410, DRB1_0421, DRB1_0423, -1.3987
58 LIYRYRFNS DRB1_0301, DRB1_0305, DRB1_0309, DRB1_0801, DRB1_0802, DRB1_0804, DRB1_0806,
DRB1_0813, DRB1_0817, DRB1_1101, DRB1_1102, DRB1_1104, DRB1_1106, DRB1_1107,
DRB1_1114, DRB1_1120, DRB1_1121, DRB1_1301, DRB1_1302, DRB1_1304, DRB1_1307,
DRB1_1311, DRB1_1322, DRB1_1323, DRB1_1327, DRB1_1328, DRB1_1501, DRB1_1506
−0.051
72 MLSSCKPIT DRB1_0301, DRB1_0305, DRB1_0309, DRB1_1107 -0.3409
132 VVVGTTDAK DRB1_0301, DRB1_0305, DRB1_0306, DRB1_0307, DRB1_0308, DRB1_0311, DRB1_1107, 1.8645
37 WHINRTALN DRB1_0305, DRB1_0309, DRB1_0401, DRB1_0405, DRB1_0408, DRB1_0410, DRB1_0421,
DRB1_0426, DRB1_0801, DRB1_0802, DRB1_0806, DRB1_0817, DRB1_1101, DRB1_1114,
DRB1_1120, DRB1_1128, DRB1_1302, DRB1_1304, DRB1_1305, DRB1_1307, DRB1_1321,
DRB1_1323
0.3868
62 YRFNSTGCP DRB1_0305, DRB1_0309, DRB1_0401, DRB1_0405, DRB1_0408, DRB1_0421, DRB1_0426, DRB1_0801,
DRB1_0802, DRB1_1101, DRB1_1120, DRB1_1128, DRB1_1302, DRB1_1305, DRB1_1307, DRB1_1321,
0.9493
105 WHYAPRSCS DRB1_0305, DRB1_0306, DRB1_0307, DRB1_0308, DRB1_0309, DRB1_0311, DRB1_0801, DRB1_0802,
DRB1_0813, DRB1_1101, DRB1_1107, DRB1_1114, DRB1_1120, DRB1_1128, DRB1_1302, DRB1_1305,
DRB1_1307, DRB1_1323
0.5807
172 WMNSTGFLK DRB1_0305, DRB5_0101, DRB5_0105 0.1523
169 WTRGERCDI DRB1_0305, DRB1_0309, 0.9138
54 FIAGLIYRY DRB1_0309, 0.4518
127 FTPSPVVVG DRB1_0309, DRB1_0421 1.3553
239 WHYPCTVNF DRB1_0309, DRB1_0405, DRB1_0421, DRB1_0703 0.7657
167 WFGCVWMNS DRB1_0401, DRB1_0408, DRB1_1101 0.2989
60 YRYRFNSTG DRB1_0402, DRB1_0405, DRB1_0408, DRB1_0421, DRB1_0801, DRB1_0802, DRB1_0806, DRB1_0813,
DRB1_0817, DRB1_1120, DRB1_1302, DRB1_1502
1.5053
247 FTLFKVRMF DRB1_0402, DRB1_0701, DRB1_0703, DRB1_0801, DRB1_0802, DRB1_1101, DRB1_1102, DRB1_1114,
DRB1_1120, DRB1_1121, DRB1_1128, DRB1_1301, DRB1_1302, DRB1_1304, DRB1_1305, DRB1_1307,
DRB1_1323, DRB1_1327, DRB1_1328
0.0943
256 VGGFEHRLS DRB1_0402, DRB1_1102, DRB1_1114, DRB1_1120, DRB1_1121, DRB1_1301, DRB1_1302, DRB1_1304,
DRB1_1322, DRB1_1323, DRB1_1327, DRB1_1328
1.3166
252 VRMFVGGFE DRB1_0405, DRB1_0410, DRB1_0801, DRB1_0806, DRB1_0817, DRB1_1304, DRB1_1321,
DRB1_1501, DRB1_1502, DRB1_1506
-0.4355
147 WGENETDVF DRB1_0421 −0.0038
125 YCFTPSPVV DRB1_0701, DRB1_0703 1.2112
241 YPCTVNFTL DRB1_0701, DRB1_0703 0.9270
259 FEHRLSAAC DRB1_0801, DRB1_0802, DRB1_0813 1.8179
277 IEDRDRSEQ DRB1_0813 0.5283
103 YCWHYAPRS DRB1_1114, DRB1_1120, DRB1_1302, DRB1_1323 1.3992
190 YGGNGRRGN DRB1_1114, DRB1_1120, DRB1_1302, DRB1_1304, DRB1_1323 2.2420
209 FRKHPEATY DRB1_1114, DRB1_1120, DRB1_1302, DRB1_1323, 0.8056
236 YRLWHYPCT DRB1_1502, DRB1_1506 0.5131
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Table 5 MHC Class II epitopes with antigenicity scores (Continued)
245 VNFTLFKVR DRB5_0101, DRB5_0105 0.9765
59 IYRYRFNST DRB1_1501, DRB1_1502, DRB1_1506 0.9405
55 IAGLIYRYR DRB5_0101, DRB5_0105 1.4380
Non-Antigens are shown in bold face.
Table 6 Highly conserved epitopes from E2 of 3a and 1a
Epitopes B-cell/T-cell
PVYCFTPSPVVV B-cell
TPSPVVVGT T-cell (HLA-B_3501, HLA-B_5101, HLA-B_5102,
HLA-B_5103, MHC-Ld)
VYCFTPSPV T-cell (DRB1_0102, DRB1_0423, DRB1_1501, DRB1_1506)
FTPSPVVVG T-cell (DRB1_0309, DRB1_0421)
YCFTPSPVV T-cell (DRB1_0701, DRB1_0703)
YRLWHYPCT T-cell (DRB1_1502, DRB1_1506)
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of E2 protein.
Epitopes prediction for the vaccine development
Humoral and cellular immunity are the two arms of im-
munity provided by B-cells and T-cells, respectively. The
recognition of pathogenic epitopes by B-cell and T-cells
lies at the heart of immune response. Such recognition
starts the mechanism of activation of humoral and cellu-
lar response and leads to ultimate destruction of patho-
genic organism [35]. Epitopes are principal components
of both subunit and poly-epitopic vaccines. Thus, it is a
pivotal challenge for immune-informatics to accurately
predict the B-cell and T-cells epitopes [37].
It is important for a protein to expose in outside envir-
onment to interact with soluble antibodies, B-cells and
T-cells. So, the membrane topology of the E2 protein
was determined using TMHMM server. In this analysis,
a total of 2 transmembrane helices with, 23 amino acids
each, were predicted. First helix spans from residue 293
to residue 315 while second helix spans from residue
328 to residue 350. A large 1 to 292 portion of the pro-
tein was outside of the membrane and a small loop like
structure was present inside the membrane. For the pre-
diction of B-cell and T-cell epitopes, only extra-
membranous region was selected. The antigenicity score
of selected (1 – 292) region was 0.4911 which indicated
that this region as a probable antigen.
B-cell epitopes prediction
B-cell epitopes are important to elicit humoral immune
response. B-Cell epitopes were predicted using BCPred
server. Using the configuration of 12 amino acids, 18
epitopes were predicted using extra-membranous region
of the protein (Table 3). Then, all epitopes were checked
for antigenicity using Vexijen server. Among them 13
were having antigenicity score greater than 0.4 threshold
value for antigens while 5 were below this limit. Epitope
DIYGGNGRRGND present at position 188 had highest
antigenicity score. A higher antigenicity score indicates the
better binding affinity between receptor and epitope [36].
T cell epitopes prediction
T-cell epitopes are presented on either MHC class I or
MHC class II which play significant role in cell-mediated
immunity [38,39]. For the prediction of T-cell epitopes,
we used ProPred server with 47 alleles for MHC class Iand 54 alleles for MHC class II. A total of 4 epitopes were
predicted for MHC class I in extra-membranous region
while only 2 epitopes, FFNQGWGPL and TPSPVVVGT,
showed antigenicity score greater than antigenicity thresh-
old (0.4) (Table 4). Similarly, 34 epitopes were predicted
for MHC class II and 24 among them were found to be
antigenic (Table 5). Out of 24 antigenic peptides, eleven
showed antigenicity score >1.000 which is considered good
in terms of stability of receptor and epitope interaction.
Conservancy and structural analysis of predicted epitopes
The assessment of epitope conservation is important in
vaccine design because a higher level of conservation en-
sure broader protection against multiple strains of a
pathogen [34]. The conservancy of the predicted epi-
topes was determined using E2 proteins from HCV 3a
and HCV 1a from various regions of the world. For this,
3a sequence from India, Japan, United Kingdom and
USA; and 1a sequence from Pakistan, France, Japan, UK
and USA were downloaded from NCBI database. The
IEDB conservancy analysis was used to determine con-
served epitopes among all selected E2 sequences from
genotypes 3a and 1a (Additional file 1: Table S1). Separ-
ate analysis of HCV genotype 3a and 1a epitopes showed
conservancy in 9 epitope sequences each. Further ana-
lysis showed that six epitopes were highly conserved for
both HCV genotype 3a and 1a (Table 6). Among 6
conserved epitopes, a B-cell epitope and an MHC-class I
(T-cell) epitope was conserved at positions 123 and 128,
respectively. Furthermore, four MHC-class II (T-cell)
epitopes were found conserved at positions 124, 125,
127 and 236. This indicates that E2 protein can elicit not
only humoral immune response but also helper-T cells
and cytotoxic-T cells too. The structural analysis of E2
Figure 5 Structural analysis of highly conserved epitopes in HCV E2 protein. The structure revealed that it contains overlapping epitopes
(A) region from 123 – 136 related to B-cells and T-cells. On the other hand, a single epitope is also present at position 236 (B) which is related
to T-cell.
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surface (Figure 5). Surface exposure of epitopes is im-
portant for interaction with respective immune cell re-
ceptors [35,36,40].
Moreover, it is generally desirable that a vaccine for-
mulation may have one or more B-cell and T-cell epi-
topes because a wide immune response can efficiently
eradicate the invading pathogen. Sometimes, a small
protein motif with overlapping epitopes for B-cells and
T-cells can stimulate the humoral and cell-mediated im-
mune response. The conserved epitopes in HCV E2 pro-
tein showed that the loop-sheet motif from 123 to 136
region contains 5 overlapping epitopes for both B-cells
and T-cells (Figure 5). This motif has one B-cell and
4 T-cell epitopes. T-cell epitopes include one MHC class
I specific and three MHC class II specific epitopes.
Hence, this motif of 13 amino acids can induce broad
immune response against HCV pathogen.
Conclusion
HCV is prevalent worldwide and there is no vaccine de-
veloped against this virus. There are multiple antigenic
components which can be used for vaccine develop-
ment. In Pakistan, HCV genotype 3a is most common
followed by 1a. The sequence, structural and epitope
analysis has revealed a number of conserved epitopes in
both 3a and 1a genotypes. These epitopes may not only
help in diagnosing the pathogens but also may help in
developing vaccine against HCV 3a and 1a. Presence of
overlapping epitopes generates the hope that a small
fragment of peptide in vaccine formulation can elicit
broad immune response and may result in efficient
clearing of pathogen.Additional file
Additional file 1: Table S1. Conservancy of E2 protein epitopes with
HCV 3a and HCV 1a sequences from various countries.
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